An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Carfilzomib
Related studies linked through entity extraction aliases.
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
- Status
- TERMINATED
- Phase
- PHASE2
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Status
- COMPLETED
- Phase
- PHASE4
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Status
- COMPLETED
- Phase
- PHASE2
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE3
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Combination Study for High Risk Multiple Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE2